Mette Kirstine Agger - Oct 7, 2025 Form 4 Insider Report for scPharmaceuticals Inc. (SCPH)

Role: Director
Signature: /s/ John H. Tucker, attorney-in-fact
Stock symbol: SCPH
Transactions as of: Oct 7, 2025
Transactions value $: $0
Form type: 4
Date filed: 10/7/2025, 04:30 PM
Previous filing: Jun 30, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Agger Mette Kirstine	Director	C/O SCPHARMACEUTICALS INC, 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON	/s/ John H. Tucker, attorney-in-fact	2025-10-07	0001722234

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SCPH	Stock Option (Right to Buy)	Disposed to Issuer	$0	-30K	-100%	$0.00	0	Oct 7, 2025	Common Stock	30K	$3.85	Direct	F1, F2
transaction	SCPH	Stock Option (Right to Buy)	Disposed to Issuer	$0	-19.8K	-100%	$0.00	0	Oct 7, 2025	Common Stock	19.8K	$4.11	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Mette Kirstine Agger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,
F2	(Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Content

In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,

(Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.